AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02795299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Acid folic (folate) 1mg to be administered once daily during the treatment period.
Study NCT02795299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: Acid folic (folate) 1mg to be administered once daily during the treatment period.
Study NCT02795299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mM acetate, 9% (w/v) sucrose, and 0.006% (w/v) polysorbate 20 at pH 5.2 ± 0.3
Study NCT01726543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Canaloplasty and phacoemulsification
Description: As soon as the two scleral flaps (deep and superficial -similar to deep sclerectomy) are dissected, the phacoemulsification is performed and a artificial lense is implanted. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and is advanced 12 clock hours within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. When the catheterisation of the canal is done, the distal tip is exposed and a 10-0 propylene suture is tied to the distal tip. Then the microcatheter is withdrawn and suture is pulled into the canal. As it appears at the other ostium of canal the microcatheter it separated from the suture. A loop is created, encircling the inner wall of Schlemm canal. Then suture loop is tightened to distend the trabecular meshwork inward, placing the tissues in tension, the locking nods are added. The superficial flap is sutured watertight to prevent bleb formation.
Study NCT01726543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-penetrating deep sclerectomy and phacoemulsification
Description: A fornix-based conjunctival ﬂap is dissected superiorly, and the sclera is exposed. A 5 x 5 mm scleral ﬂap is dissected anteriorly into clear cornea using a No. 69 Beaver blade. Then the phacoemulsification procedure is performed and a artificial lense is implanted. Afterwards second deep scleral ﬂap is dissected and excised leaving only a thin layer of deep sclera over the choroid. Anteriorly, the dissection is made down to remove Schlemm's canal and juxtacanalicular trabeculum. Excision of the corneal stroma is performed more anteriorly down to Descemet's membrane. This allows aqueous humor to percolate through the thin trabecular-Descemet's membrane. The superficial scleral ﬂap is then closed with two 10-0 monofilament nylon sutures.The conjunctiva is sutured down over the limbus with one interrupted 10-0 monofilament nylon suture at each corner.
Study NCT01569815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 400 mg once daily
Study NCT02512445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Informed Guilt Reduction Therapy
Description: Trauma focused therapy
Study NCT02512445 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care Therapy
Description: Supportive therapy
Study NCT00742170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Description: Participants are randomly assigned to receive either active or sham electroacupuncture using the Han's Acupoint Nerve Stimulator (HANS) device. The HANS method uses a non-invasive device that emits a constant electric current transcutaneously via skin electrodes to stimulate relevant acupoints: Heku (LI4) / Laogong (P8) on one hand and Neiguan (P6) / Waiguan (TE 5) on the opposite arm. Stimulation is delivered in the dense-and-disperse mode, alternating between 2 and 100 Hz at 3-second intervals. Participants receive thrice daily treatments for 4 days during inpatient opioid detoxification.
Study NCT00742170 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture
Description: Participants are randomly assigned to receive either active or sham electroacupuncture using the Han's Acupoint Nerve Stimulator (HANS) device. The HANS method uses a non-invasive device that emits a constant electric current transcutaneously via skin electrodes to stimulate relevant acupoints: Heku (LI4) / Laogong (P8) on one hand and Neiguan (P6) / Waiguan (TE 5) on the opposite arm. Stimulation is delivered in the dense-and-disperse mode, alternating between 2 and 100 Hz at 3-second intervals. Participants receive thrice daily treatments for 4 days during inpatient opioid detoxification.
Study NCT04067791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prolonged-Release Melatonin
Description: 4.47 mg melatonin in a bi-layer prolonged-release capsule
Study NCT04067791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immediate-Release Melatonin
Description: 4.47 mg melatonin in a standard release bi-layer capsule
Study NCT03667313 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: sirolimus-eluting balloon (SEB) MagicTouch
Description: Patients with coronary in-stent restenosis treated with sirolimus-eluting balloon
Study NCT03667313 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel-eluting balloon (PEB) Sequent Please
Description: Patients with coronary in-stent restenosis treated with paclitaxel-eluting balloon
Study NCT00876707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis implant
Description: Implant of diffractive multifocal IOL Tecnis
Study NCT00876707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReSTOR implant
Description: Implant of multifocal IOL ReSTOR
Study NCT00876707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReZoom implant
Description: Implant of multifocal IOL ReZoom
Study NCT02375373 — intervention group
Intervention type: OTHER
Intervention: Observational Chickpea Diet
Description: Individuals encouraged to maintain increased legume intake and explore new recipes that allow them to maintain a diverse menu of legume based foods.~Fecal samples collected monthly.
Study NCT00169702 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weight management program
Description: 12 sessions, psychoeducation
Study NCT00169702 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: weight management program
Description: 12 sessions, psychoeducation
Study NCT00169702 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: weight management program
Description: 2 weekly, 12 sessions, psychoeducational weight management
Study NCT01669694 — intervention group
Intervention type: OTHER
Intervention: Pelvic floor PT with biomarkers
Description: Pelvic floor physical therapy and collection of urine for biomarker analysis.
Study NCT00742924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00742924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Surgery of the primary tumor is scheduled for 12 weeks after the commencement of chemotherapy.
Study NCT03867110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Study NCT03254862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSS/AsynS
Description: 16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Sequential Stimulation (ASynS) on the other leg
Study NCT04048382 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: The booklet given is a 2-page booklet including the following information: 1) overview of PrEP; 2) eligibility for PrEP; 3) efficacy of PrEP; 4) safety of PrEP; and 5) obtaining, initiating, and adhering to PrEP. Participants will also be provided with both verbal and written information regarding available sexual health and HIV prevention services, including PrEP, at Family Health Centers of San Diego (FHCSD). Comprehensive HIV-prevention healthcare, including PrEP, is available to study participants at FHCSD at no or minimal cost. If a UC participant is diagnosed with a sexually transmitted infection, including HIV, treatment and follow-up will be coordinated by FHCSD staff as per usual care procedures.
Study NCT03254862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSS/AsynR
Description: 16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Random Stimulation (ASynR) on the other leg.
Study NCT01676792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-T100 gel with 2.3% of SM in Solanum undatum plant extract
Description: Self administered topical SR-T100 gel on lesion(s) including its peripheral normal skin approximately 1cm around the lesion with the amount of 0.02 g/cm squared with occlusive dressing once daily. Patients who is unable to tolerate with occlusive dressing is instructed 3 times daily in the morning, afternoon \& before bed time. Medication should be reapply after bathing or cleaning.
Study NCT01454024 — intervention group
Intervention type: DEVICE
Intervention: FlexPen®
Description: Prescribed insulin treatment delivered by FlexPen® as part of routine clinical practice
Study NCT01454024 — intervention group
Intervention type: DEVICE
Intervention: NovoPen® 3
Description: Prescribed insulin treatment delivered by NovoPen® 3 as part of routine clinical practice
Study NCT02824848 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive Stretching
Description: Passive stretching and associated strengthening activities to change head/neck and body alignment
Study NCT02824848 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Perception-Action Approach
Description: Environmental set-up and gentle manual guidance to promote spontaneous exploration of alternative head/neck and body alignment possibilities
Study NCT01998438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: The loading doses were given in 15 minutes when incision.
Study NCT02711605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltraShape focused ultrasound device
Description: 3 biweekly focused ultrasound treatments to the male chest with UltraShape.
Study NCT01990755 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT (Cognitive Behavioral Therapy)
Description: It is a worldwide known form of psychotherapy for eating disorders
Study NCT01990755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IBPP (individual psychology brief psychotherapy)
Description: It is a worldwide known form of psychotherapy for eating disorders
Study NCT01990755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBT + OLANZAPINE
Description: It is a worldwide known form of psychotherapy for eating disorders associated with a new antipsychotic with good efficacy on anorexia nervosa
Study NCT04131153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: three-step radiofrequency ablation
Description: After destroying the main blood supply of the tumor, extracting the blood in the tumor, reducing the blood flow in the tumor and shrinking the tumor volume, the remaining tumor was then treated with radiofrequency ablation, namely the three-step radiofrequency ablation with one block, two inhalation and three damages.
Study NCT01990755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutritional rehabilitation
Description: all patients were followed-up monthly with nutritionist and dietitian visits
Study NCT00742924 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT01990755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: delorazepam
Description: all patients were followed-up with psychiatric visits with symptomatic drug administration (tranquillizer: delorazepam) where necessary
Study NCT04319406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: Test group will be administered 12.5% Dextrose mainly into superior joint space according to symptoms of patient at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
Study NCT04319406 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Only dry needling will be performed at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
Study NCT01253187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)
Description: Treatment group A: Single 1 film-coated tablet (Ethinylestradiol \[EE\] 0.02mg / Drospirenone \[DRSP\] 3mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
Study NCT01253187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)
Description: Treatment group B: Single 1 film-coated tablet (Ethinylestradiol \[EE\] 0.02mg / Drospirenone \[DRSP\] 3mg / L-5-methyltetrahydrofolate \[L-5-MTHF\] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
Study NCT01253187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-5-MTHF 0.451mg (Metafolin)
Description: Treatment group C: Single 1 coated tablet (L-5-methyltetrahydrofolate \[L-5-MTHF\] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
Study NCT04460248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib, Lenalidomide and Rituximab (ZR2)
Description: Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~1. Zanubrutinib, 160 mg bid, po, day 1-21;~2. Lenalidomide, 25 mg qd, po, day 2-11;~3. Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days, for a maximum of 2 years.
Study NCT04271670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ginger powder footbaths
Description: 20-minute footbath with 12 liters of 40°C warm water and an additive of 80g dried ginger powder (reaching up to mid-calf level)
Study NCT04271670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mustard powder footbaths
Description: 20-minute footbath with 12 liters of 40° C warm water and an additive of 80g dried mustard powder (reaching up to mid-calf level)
Study NCT04271670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm water only footbaths
Description: 20-minute footbath with 12 liters of 40° C warm water without any additive (reaching up to mid-calf level)
Study NCT04768530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root Planing
Description: Supra- and sub-gingival calculus and debris were removed
Study NCT04768530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide hydrogel
Description: Scaling and root planing was performed in combination with the subgingivally delivered thermosensitive Nitazoxanide hydrogel as adjunct antimicrobial therapy.
Study NCT04018703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: loading dose 0.5-2.5ug/kg followed by continuous infusion 0.2-0.5ug/kg/h
Study NCT00742924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV
Study NCT03633734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential Treatment
Description: One cycle of the treatment lasts for 56 days. Patients will receive chemotherapy based on Nab-paclitaxel Plus Gemcitabine and modified Folfirinox in sequence order. The cycle will repeat until progression or intolerance of toxicity.
Study NCT02948153 — intervention group
Intervention type: OTHER
Intervention: clinical study
Description: It is a comprehensive study in a large sample using multiple techniques to assess various aspects of the disease. All patients underwent the following : Induced Sputum, spirometry, fractional exhaled nitric oxide (FeNO), prick test, total IgE and blood albumin. Analysis of mucins and TLRs
Study NCT02029573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg po daily until disease progression or unacceptable toxicity. (starting dose of 40 mg po daily for the first 21 days)
Study NCT02029573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
Study NCT02029573 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 60 Gy in 30 fractions
Study NCT02631967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kono anastomosis
Description: Kono anastomosis
Study NCT02631967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stapled side-to-side anastomosis
Description: Stapled side-to-side anastomosis
Study NCT00838435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapropterin dihydrochloride
Description: A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
Study NCT00974974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX066
Description: extended-release carbidopa-levodopa capsules
Study NCT00974974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPX066
Description: extended-release carbidopa-levodopa capsules
Study NCT00974974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IR CD-LD
Description: immediate-release carbidopa-levodopa tablets
Study NCT00974974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IR CD-LD
Description: immediate-release carbidopa-levodopa tablets
Study NCT01691820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Samples collected at Months 0, 4, 8, 12, 16, 20, 24, 28, 32, and 36.
Study NCT01691820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urine collection
Description: Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
Study NCT01691820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saliva collection
Description: Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
Study NCT02309775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy
Description: First cleaning of the ear is made with 70% alcohol. The seed will be stuck in the ear with an adhesive (Micropore 3M) tape. The placement, points according to Souza (1997), were: Shen Men, Sympathetic, Kidney, Subcortex, Adrenal and Cerebral. As sessions will held twice a week for a total of 10 sessions.
Study NCT00757757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: Anti-M-CSF antibody
Study NCT03559621 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: mobile-based lifestyle intervention
Description: one face-to-face coaching within 2 weeks after randomization, monthly telephonic coaching -and continuous use of the app as needed
Study NCT03294486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)
Description: Phase 1, TG6002 administered in a total volume of 250mL of saline solution (0.9 %) as three intravenous infusions at the following doses:~* Dose 1 : 5.0 log10 pfu •Dose 2 : 6.0 log10 pfu •Dose 3 : 7.0 log10 pfu •Dose 4 : 7.5 log10 pfu~* Dose 5 : 8.0 log10 pfu •Dose 6 : 8.5 log10 pfu Additional dose levels •Dose 2-1 : 5.5 log10 pfu •Dose 3-2 : 6.5 log10 pfu Phase 2a, treatment IV at the recommended Phase 2 dose 5-Flucytosine (5-FC) is provided in its commercial packaging with brand name ANCOTIL 500 mg, tablet (Ancotil®) marketed by MEDA Pharma: polypropylene tube containing 100 tablets.~  5-FC administered orally as 500 mg tablets taken 4 times per day (qid). Daily starting dose is 200 mg/kg. The daily dose will be adjusted at Day 19 following the measurement of 5-FC plasma concentration at steady state (Day 7), which should be kept below 100 mg/L.
Study NCT01633736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care plus progresive resistance training
Description: Duration 8 weeks; two weeks of familiarisation with the intervention protocol without resistance (for familiarisation and neural adaptation) followed by 6 weeks progressive resistance (PR). The three times a week PR training will be as a home exercise program with fortnightly home visits to monitor/progress PR training. It comprises a 4 minute warm up and cool down with one exercise targeting the hip abductors and one the lateral rotators. Exercise prescription will follow existing guidelines for progressive PR training. Parents will be taught supervision by the researcher using clear explanations in words and pictures in a logbook. Logbooks have been found to facilitate compliance, dosage and motivation.
Study NCT00606359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, split-virion influenza virus
Description: 0.1 mL, Intradermal. 2 vaccinations 12 months apart
Study NCT00606359 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated, split-virion influenza virus
Description: 0.5 mL, Intramuscular. 2 vaccinations, 12 months apart